• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1116956 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type% u7 t! f5 h5 P$ K, U
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 * w- M0 e4 M  h5 b
+ Author Affiliations
& P( M7 u8 W' d) N( g  ]* H+ }: x/ L; c  p  q! L9 K; a
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan 2 |1 ^+ B7 _6 ?0 ?
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan ) B, f- x/ R* t4 {) G0 n: I
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 9 B3 }; |! I& e0 j+ K4 |' h! ]) b' E
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
  Q& G9 Y' C7 C' D5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
. b0 d5 |( f: E* x6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
& N& Z0 U) Z/ u6 Q( ]' _7Kinki University School of Medicine, Osaka 589-8511, Japan
7 G# o* o5 ^: B* n- J8Izumi Municipal Hospital, Osaka 594-0071, Japan
5 ^) J/ @# P/ ]0 A6 _9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan , ^" E' \* z' I$ P6 X
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp ! I9 o; i  a  e. Y+ n, M4 H1 Y
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
1 n/ n3 p- e/ p; |/ E$ l. n
5 l* ]+ c" G: M! {8 Y, u
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
0 m  {! I7 M7 S" x- E7 I
- k' \6 E9 P+ \8 ?" G' J. c9 s5 \" EAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
$ m9 O( Y6 ~4 l! a$ ]
7 Y3 L, x* h. W3 W6 W0 CAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  4 w9 z9 P4 C% P9 n* C

6 Z  i" W! ]- O. V4 o7 V5 y7 zPublished online on: Thursday, December 1, 2011 " ~+ a7 d! R  W5 ?

. {/ c3 R' r9 l& N( GDoi: 10.3892/ol.2011.507   V, i0 p/ p. j8 h5 T: ~. {
, x( w- ]+ ?- x. T$ F
Pages: 405-410 % T, t; I: u8 ^3 S% ]
; Y  o( r; J% B1 A, F
Abstract:
" z0 f& |- H. NS-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma." V' U& [" t3 {8 ^, F8 a' i% D
3 p' p& X" E" X9 `& i! l* n8 a
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
2 R  c% ~! U5 j% {7 r# Z; K  W9 I2 }( |F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 : j5 X; \( Z4 j( w% n! g+ }+ K
+ Author Affiliations1 c' `/ D7 `$ A% w
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu ; n1 j1 y: z' ~& |# T7 [" F' I4 K
2Department of Thoracic Surgery, Kyoto University, Kyoto 5 B) |( Y- r( q  ?. G$ N: W2 F
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan % P6 J$ @- `; ?+ d# K# ^- `
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp $ c& f- P# i# |! P
Received September 3, 2010. / O# g8 N" v$ ^( q( ^* ]  H
Revision received November 11, 2010. 6 Z9 S+ M* f7 R- H
Accepted November 17, 2010. 4 s2 j3 B* Y) U$ H! O2 {
Abstract" o! p3 C  B/ t# w
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. ' Q  T% ?2 m; x  [0 ~6 }5 z
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
8 i0 r& {/ D# o! }- H' WResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
% a8 x: E) E+ V5 e5 w2 D* SConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
* L: ^# n( [$ |) M/ G
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
) m9 Q  ?8 Q% U3 W! `+ M6 x, C今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
$ q- _% x: }, Y; E$ t0 I6 [
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy1 \5 H0 F9 o- O. ~
http://clinicaltrials.gov/ct2/show/NCT01523587* j- n/ A8 a$ p5 a$ Y8 J5 y
# r( r8 s, M5 {# @. p+ j' B
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
4 k0 H: H7 i  h0 ^6 zhttp://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑
+ e  S: ]5 z9 z* A1 j$ O6 X3 d5 R  ~$ X
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
7 j# [+ }+ R/ v至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53
8 Y# I6 e+ |" R+ N从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
* E0 W. Q0 N9 N9 H" n9 N至今为止,未出 ...

' t/ p; T* S7 t4 s' @4 q" @没有副作用是第一追求,效果显著是第二追求。
: [6 z% d, m& N; n不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表